- Home
- SNES vs TSBX Comparison
SNES vs TSBX Comparison
Compare SNES & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- TSBX
- Stock Information
- Founded
- SNES 2004
- TSBX 2015
- Country
- SNES United States
- TSBX United States
- Employees
- SNES N/A
- TSBX N/A
- Industry
- SNES Agricultural Chemicals
- TSBX
- Sector
- SNES Industrials
- TSBX
- Exchange
- SNES Nasdaq
- TSBX Nasdaq
- Market Cap
- SNES 6.7M
- TSBX 7.7M
- IPO Year
- SNES 2016
- TSBX 2023
- Fundamental
- Price
- SNES $4.80
- TSBX $0.36
- Analyst Decision
- SNES Strong Buy
- TSBX Buy
- Analyst Count
- SNES 1
- TSBX 3
- Target Price
- SNES $10.00
- TSBX $4.75
- AVG Volume (30 Days)
- SNES 228.1K
- TSBX 859.0K
- Earning Date
- SNES 08-07-2025
- TSBX 08-13-2025
- Dividend Yield
- SNES N/A
- TSBX N/A
- EPS Growth
- SNES N/A
- TSBX N/A
- EPS
- SNES N/A
- TSBX N/A
- Revenue
- SNES $1,927,000.00
- TSBX N/A
- Revenue This Year
- SNES $130.53
- TSBX N/A
- Revenue Next Year
- SNES $80.00
- TSBX N/A
- P/E Ratio
- SNES N/A
- TSBX N/A
- Revenue Growth
- SNES 40.15
- TSBX N/A
- 52 Week Low
- SNES $1.30
- TSBX $0.29
- 52 Week High
- SNES $6.48
- TSBX $3.00
- Technical
- Relative Strength Index (RSI)
- SNES 76.68
- TSBX 44.06
- Support Level
- SNES $3.56
- TSBX $0.35
- Resistance Level
- SNES $4.46
- TSBX $0.38
- Average True Range (ATR)
- SNES 0.38
- TSBX 0.03
- MACD
- SNES 0.10
- TSBX -0.00
- Stochastic Oscillator
- SNES 97.61
- TSBX 3.67
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.